UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

PURPOSE: In spite of advances in therapy for some subtypes, group 3 medulloblastoma continues to portend a poor prognosis. A subpopulation of medulloblastoma cells expressing the cell surface marker CD133 have been posited as possible stem cell like cancer cells (SCLCC), a potential source of drug r...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Transl Oncol
Autori principali: Williams, Adele P., Garner, Evan F., Stafman, Laura L., Aye, Jamie M., Quinn, Colin H., Marayati, Raoud, Stewart, Jerry E., Atigadda, Venkatram R., Mroczek-Musulman, Elizabeth, Moore, Blake P., Beierle, Elizabeth A., Friedman, Gregory K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Neoplasia Press 2019
Soggetti:
Original article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6664160/
https://ncbi.nlm.nih.gov/pubmed/31362265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.07.003
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi